Bioethics News

When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs

With a flagship treatment that helps fewer than 11,000 people, how is Alexion making so much money?

Source: Bioethics Bulletin by the Berman Institute of Bioethics.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.